More

    Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm By Investing.com



    NEW YORK, May 26, 2024 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Verrica Pharmaceuticals , Inc. (NASDAQ: NASDAQ:) on behalf of long-term stockholders following a class action complaint that was filed against Verrica with a Class Period from May 28, 2021 to May 24, 2022. Our investigation concerns whether the board of directors of Verrica have breached their fiduciary duties to the company.

    In December 2020, Verrica submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking regulatory approval of VP-102 for the treatment of molluscum.

    On September 20, 2021, after the market closed, Verrica announced receipt of a Complete Response Letter (CRL) due to deficiencies at a facility of Verrica’s contract manufacturer in connection with the Company’s NDA.

    On this news, the Company’s stock price fell $1.00, or 8.3%, to close at $11.03 per share on September 21, 2021, on unusually heavy trading volume.

    In November 2021, Verrica resubmitted the NDA for VP-102, claiming [t]he resubmission addresses the successful resolution of inspection deficiencies at the manufacturing facility.

    Then, on May 24, 2022, after the market closed, Verrica announced receipt of another Complete Response Letter regarding the VP-102 NDA citing deficiencies identified during a general reinspection of Sterling Pharmaceuticals Services, LLC (Sterling), the contract manufacturing organization (CMO) that manufactures Verrica’s bulk solution drug product.

    On this news, the Company’s shares fell $3.55, or 63.8%, to close at $2.01 per share on May 25, 2022, on unusually heavy trading volume.

    The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that there were manufacturing deficiencies at the facility where Verrica’s contract manufacturer produced bulk solution for VP-102; (2) that these deficiencies were not remediated when Verrica resubmitted its NDA for VP-102 for molluscum; (3) that the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

    If you are a long-term stockholder of Verrica, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

    About Bragar Eagel & Squire, P.C.:

    Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

    Contact Information:

    Bragar Eagel & Squire, P.C.
    Brandon Walker, Esq.
    Marion Passmore, Esq.
    (212) 355-4648
    investigations@bespc.com
    www.bespc.com


    https://i-invdn-com.investing.com/news/LYNXMPEA6D16T_L.jpg



    Source link
    Investing.com

    Latest articles

    spot_imgspot_img

    Related articles

    spot_imgspot_img